A consortium of financial trade groups has begun lobbying the European Commission to implement the sort of changes that triggered the U.S. biotech IPO boom. The European IPO Task Force specifically wants politicians to slash the regulatory and administrative cost of going public by up to 50%, a move that would make it financially feasible for more small companies to float.
Amgen's deCODE Genetics has published a series of papers that hint at how the the Big Biotech could begin to recoup the $415 million it paid for the population-scale sequencing pioneer. For Amgen, the meat of the project lies in the discovery of 8,000 human knockouts, people who lack a working version of one of 1,171 genes.
Cellectis, a French company with a proprietary spin on one of biotech's hottest fields, made an up-sized debut on Wall Street, grossing more than $228 million.
Novartis became the first to win approval among a scrum of drugmakers with new antibody treatments for autoimmune disease, but its rivals are bounding toward the FDA with positive data of their own.
Maryland's Emergent BioSolutions won FDA approval for an injected treatment for anthrax infection, padding the company's stable of biodefense products.
Harvard professor Doug Melton is having quite a week. His work on potential cell therapies for diabetes just fueled the launch of a well-funded biotech startup, and now he's signed up with AstraZeneca to help the drugmaker spotlight new treatments for the disease.
GlaxoSmithKline is looking for some new partners in academia, launching a contest for would-be collaborators with early-stage projects that could translate into marketable medicines.
Novartis CEO Joseph Jimenez presides over one of the industry's largest R&D budgets, committing about $10 billion a year to drug development. But the American-born executive, in contrast to his predecessor, has made a habit of ditching projects when they start to look futile, a philosophy that trickles down to Novartis' lab work.
Cellectis has tossed aside its earlier IPO targets as strong demand and a surge in its European stock price have encouraged it to pitch for a bumper listing. The French CAR-T player is now aiming to raise $197 million before the overallotment, 70% more than it was targeting when it first filed its papers last month.
While biotech companies herald early-stage advances in Alzheimer's disease R&D, neuroscientists remain sharply divided as to just which protein--beta amyloid or tau--most contributes to the disorder's memory-destroying effect, and a new study has rekindled the debate.
Cambridge, MA's Blueprint Medicines is lining up to raise $100 million in an IPO to advance a stable of personalized cancer treatments and build out its pipeline.
Joint Polish Investment Fund Management is claiming a first. The Warsaw, Poland-based group has reportedly become the country's first institutional venture capital fund dedicated to life sciences after it held the initial closing of its $42 million (€38 million) investment vehicle.
Calico, the Google-backed biotech with ambitions to decode the aging process, has aligned itself with California's QB3, a Bay Area brain trust, to further flesh out its R&D mission.
Thomson Reuters is predicting a big year for blockbuster drugs. Its analysts forecast 11 drugs approved this year will go on to rack up blockbuster sales in 2019, with new treatments from Bristol-Myers Squibb, Sanofi and Novartis leading the pack.
Novo Nordisk, not long for the world of autoimmune R&D, has found a new home for one of its early-stage programs, handing it over to Bristol-Myers Squibb for an undisclosed sum.
EP Vantage's Amy Brown joins FierceBiotech Radio to talk about her retrospective look at a big year for biotech and peek ahead at what might be in store for 2015.
Cambridge, MA, biotech Semma Therapeutics is developing a stem cell technology that could help diabetics return to producing their own insulin, and the nascent company picked up $44 million and a handshake with Novartis to get rolling.
FierceBiotech Editor in Chief John Carroll sits down with Bloomberg Intelligence analyst Asthika Goonewardene to discuss the results of an informal survey in which readers weighed in on whether the unprecedented bull marketfor biotech is sustainable or has transformed into a fragile bubble ready to pop.
GlaxoSmithKline has reached out to the storied Cold Spring Harbor Laboratory to collaborate on a potential treatment for Type 2 diabetes and obesity, inking a multiyear R&D deal.
Shares in Silence Therapeutics jumped more than 20% on the back of Phase IIa data. The small trial was designed primarily to assess the safety and pharmacokinetics of the pancreatic cancer drug, but that did little to deter investors from latching on to some encouraging early efficacy data.